馃INTUITIVE SURGICAL ANALYSIS 馃
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer.
Last report: 30 September 2024
Based on a sample of the last year [Sept/24 TTM], its average margins have been:
- Gross margin: ≈ 66.7%
- Operating margin: ≈ 25.5%
- EBITDA margin: ≈ 31.4%
- Net margin: ≈ 27.8%
Pros:
- Advanced Technology with Da Vinci 5 System positions Intuitive Surgical as a leader in robotic-assisted surgery, potentially improving surgical outcomes and patient experiences
- Zero net debt
- Excellent margins
Cons:
- Supply chain challenges and financial pressures on hospitals due to rising operating costs and inflation
- Stable margins without great expectations of expansion
- High valuations
Based on the last report, their normalized annual EPS was ≈ $6.29 USD and its last average ROIC [TTM] was ≈ 16.28%. If an annual average Forward PER 60 is set as a benchmark with an EPS intensity of ± 0.2543x, the potential forward spread target for the next 12 months could be:
- Optimistic: ≈ $513.45 USD
- Neutral: ≈ $409.34 USD
- Pessimistic: ≈ $305.24 USD
At least, an EPS of $1.724 USD is required for the next quarter, to keep the metrics.
In other hand, if an annual average Forward EV/EBITDA 55 is set, an EBITDA increases of ± 19%, a Net Debt increases of 0%, a Dividends increase of 0% and Shares Outstanding increases of ± 1.02%, the potencial spread price target for the next 12 months could be:
- Optimistic: ≈ $460.75 USD
- Neutral: ≈ $393.60 USD
- Pessimistic: ≈ $325.03 USD
Finally, according to its current P/S ratio, a possible spread for the next 12 months might be at:
- P/S 25: ≈ $552.17 USD
- P/S 15: ≈ $331.30 USD
The best analysis is yours!
J. Joel Padilla
Copyright: Joel Padilla 2024
Comentarios
Publicar un comentario